Interaction between ganciclovir and foscarnet as inhibitors of duck hepatitis B virus replication in vitro | Zendy

Gilda Civitico | Zendy; Timothy J. Shaw | Zendy; Stephen Locarnini | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Interaction between ganciclovir and foscarnet as inhibitors of duck hepatitis B virus replication in vitro

Author(s) -

Gilda Civitico,

Timothy J. Shaw,

Stephen Locarnini

Publication year - 1996

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.40.5.1180

Subject(s) - foscarnet , ganciclovir , virology , duck hepatitis b virus , hepatitis b virus , in vivo , hbeag , hbsag , in vitro , biology , hepatitis b , viral replication , pharmacology , virus , hepadnaviridae , human cytomegalovirus , biochemistry , microbiology and biotechnology

Safe and effective treatments for chronic hepatitis B virus (HBV) infection have yet to be developed. Both ganciclovir (9-[1,3-dihydroxy-2-propoxymethyl]guanine) and foscarnet (trisodium phosphonoformate hexahydrate) are potent inhibitors of hepadnavirus replication when used individually in vitro and in vivo. However, the clinical usefulness of each drug is reduced by dose-limiting toxicity, especially during long-term monotherapy. Here we demonstrate additive inhibition of duck HBV DNA replication in cultures of primary duck hepatocytes congenitally infected with duck HBV by combinations of ganciclovir and foscarnet at low, clinically achievable concentrations. These results suggest that the effects of ganciclovir and foscarnet against HBV may be additive in vivo.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research